Canary Cure Therapeutics is a late-stage preclinical biotechnology company pioneering a paradigm shift in the treatment of obesity and metabolic diseases. While first-generation therapies have validated the massive market potential for weight loss, they leave significant gaps in long-term metabolic health—most notably the loss of lean muscle mass and the burden of frequent dosing.

At Canary Cure, we are moving beyond appetite suppression toward metabolic reprogramming for rapid and healthy weight loss while preserving muscle. Through our proprietary Chorus-siRNA platform, we develop first-in-class RNA interference (RNAi) therapies that "reprogram" energy-storing white fat into energy-burning beige fat. Canary Cure is actively seeking strategic development partners and investors for a Series A financing round to advance our lead program into the clinic.